Secondary Private Group
|
|
26
|
23399
|
31 January 2024
|
BCN Response Time
|
|
4
|
284
|
24 April 2024
|
Oral thrush - Candida. What next?
|
|
8
|
1015
|
22 April 2024
|
Eribulin
|
|
3
|
959
|
12 April 2024
|
Atrophy
|
|
11
|
468
|
31 March 2024
|
Exemestane (aromasin) and Everolimus (Afinitor)
|
|
15
|
927
|
20 March 2024
|
Is Enhertu available in the UK, on the NHS
|
|
20
|
842
|
18 March 2024
|
Have you recieved elacestrant (orserdu)?
|
|
0
|
121
|
18 March 2024
|
Xgeva (denosumab) and low White blood count
|
|
1
|
168
|
16 March 2024
|
Change of treatment - PICC or central line
|
|
12
|
272
|
16 March 2024
|
Capecitabine older people
|
|
7
|
249
|
16 March 2024
|
CA15-3 marker
|
|
7
|
519
|
16 March 2024
|
Weight gain in short space of time ?
|
|
5
|
597
|
13 March 2024
|
Tamoxifen Brand Change
|
|
3
|
161
|
10 March 2024
|
Post surgery anxiety
|
|
6
|
314
|
18 February 2024
|
Terrible balance problem
|
|
7
|
349
|
8 February 2024
|
Cancer Research Awareness
|
|
0
|
141
|
4 February 2024
|
Xeloda and bone recurrence
|
|
3
|
311
|
31 January 2024
|
Atezolizumab and Nab-paclitaxel (Abraxane) experience
|
|
5
|
902
|
30 January 2024
|
About to start Trodelvy, any information please
|
|
6
|
3322
|
28 January 2024
|
Xeloda delay
|
|
13
|
468
|
21 January 2024
|
Enhertu
|
|
20
|
15219
|
14 January 2024
|
The dreaded canula
|
|
12
|
484
|
11 January 2024
|
Sacituzumab govitecan (Trodelvy)
|
|
3
|
399
|
11 January 2024
|
HER2-low trastuzumab deruxtecan (Enhertu)
|
|
1
|
1210
|
1 January 2024
|
Covid 19
|
|
7
|
471
|
31 December 2023
|
Ribociclib dose reduced
|
|
7
|
407
|
29 December 2023
|
Succesful on Capecitabine
|
|
23
|
1390
|
24 December 2023
|
Xeloda dosage
|
|
5
|
312
|
19 December 2023
|
Letrozole advantages
|
|
12
|
817
|
17 December 2023
|